Xeomin (incobotulinumtoxinA) / Merz Pharma - LARVOL DELTA

Switox: Retrospective Analysis of Botulinum Toxin Switching in Management of Spasticity. (PubMed, Toxins (Basel)) - "The majority of patients switched from Botox to Xeomin (73.66%), while others switched from Botox to Dysport (14.63%) or from Xeomin to Dysport (11.71%). While differences between groups were observed, they were not statistically significant. Placebo and nocebo effects may influence perceptions of efficacy and side effects during treatment changes."

Journal • Retrospective data • Fatigue • Movement Disorders

Innovative Botulinum Toxin Injection: A Promising Nonsurgical Solution for Carpometacarpal Osteoarthritis. (PubMed, Clin J Sport Med) - "This case report introduces a novel approach involving intra-articular incobotulinumtoxinA (BoNTA) injection for CMCJ OA, resulting in significant and prolonged pain relief and enhanced functionality. This groundbreaking intervention effectively bridges the gap between nonsurgical and surgical treatments, offering a promising alternative for individuals with CMCJ OA."

Journal • Immunology • Osteoarthritis • Pain • Rheumatology

Intradermal Microdroplet Injection of Standard-Diluted Incobotulinumtoxin A for the Treatment of Erythematotelangiectatic Rosacea: A Study From a Dermatology Center in Medellín, Colombia. (PubMed, Cureus) - "Standard 2mL dilution INCO, used for aesthetic indications, may be a safe and effective option for treating ETR-related erythema and flushing."

Journal • Dermatology • Rosacea

Successful Treatment of Sialorrhea with Daxibotulinum Toxin A (AAN 2025) - "Currently, IncobotulinumtoxinA (USA and Europe) and RimabotulinumtoxinB (USA) are approved for this indication. All surveys suggest DaxibotulinumtoxinA provided sustained improvement of sialorrhea and may provide a novel alternative option for those refractory to other treatments."

CNS Disorders • Movement Disorders • Parkinson's Disease

Insights from Clinical Experience with DaxibotulinumtoxinA for the Treatment of Cervical Dystonia (AAN 2025) - "Our cohort consisted of both toxin-naïve and toxin-experienced individuals allowing for a broad evaluation of dosing strategies and treatment outcomes.Patients received doses ranging between 60-570U, with toxin-experienced individuals transitioning from OnabotulinumtoxinA or IncobotulinumtoxinA using a conversion ratio ranging from 1:1 to 1:3. Daxxify is a good treatment option in patients with CD, particularly in patients unsatisfied with the outcomes of previous therapies. Further studies may be warranted to explore its broader applications in the treatment of other conditions and to optimize dosing strategies for individualized patient care."

Clinical • CNS Disorders • Dystonia • Gastrointestinal Disorder • Infectious Disease • Migraine • Movement Disorders • Pain • Parkinson's Disease

Ultrasound-Guided Botulinum Toxin Infiltrations in Essential Tremor Patients: A 36-week Follow Up. (PubMed, Tremor Other Hyperkinet Mov (N Y)) - "Essential tremor patients often face limited options, as oral therapies often yield only partial efficacy, and invasive interventions, like Deep Brain Stimulation, may not always be viable. In this open-label study, 18 patients received ultrasound-guided IncobotulinumtoxinA injections, showing significant tremor improvement and enhanced quality of life, with minimal adverse events reported."

Journal • Essential Tremor • Movement Disorders • Pain

Pilot Study on the Efficacy of Incobotulinumtoxin-A for Refractory Chronic Migraine (AAN 2025) - "Onabotulinumtoxin-A was approved by the FDA in 2010 and is the only type of botulinum toxin approved for migraine, with its efficacy demonstrated in multiple clinical trials, meta-analyses, and real-world studies (3). Incobotulinumtoxin-A proved to be effective, it has a lower price than other types of toxins and does not require a cold chain, making it a better candidate for centers that do not have the correct cold chain storage facilities."

Clinical • CNS Disorders • Migraine • Pain

Secondary Treatment Failure with AbobotulinumtoxinA, IncobotulinumtoxinA, and OnabotulinumtoxinA: A Systematic Review and Meta-analysis (AAN 2025) - "Our meta-analysis found that incobotulinumtoxinA was associated with a significantly lower risk of developing STF compared with abobotulinumtoxinA (CD and spasticity) and onabotulinumtoxinA (CD). IncobotulinumtoxinA is recommended to avoid developing neutralising antibody-induced STF, particularly for patients who require higher doses and repeated treatments."

Retrospective data • Review • CNS Disorders • Dystonia • Movement Disorders

A Systematic Review and Meta-analysis of Neutralizing Antibodies After Treatment with AbobotulinumtoxinA, IncobotulinumtoxinA and OnabotulinumtoxinA Across Multiple Indications (AAN 2025) - "Our meta-analysis identified no patients exclusively treated with incobotulinumtoxinA that developed persistent NAbs, supporting the low antigenicity of this BoNT-A formulation. The potential cumulative exposure to different BoNT-A formulations for different indications is something that clinicians need to be increasingly aware of. Therefore, incobotulinumtoxinA may be recommended to avoid developing immunogenicity, particularly for patients who require higher doses and repeated treatments."

Retrospective data • Review • CNS Disorders • Dystonia • Movement Disorders

Pilot Study on the Efficacy of Incobotulinumtoxin-A for Refractory Chronic Migraine (AAN 2025) - No abstract available

Clinical • CNS Disorders • Migraine • Pain

Cross induction of anti-complexing antibodies in botulinum treatment patients injected with botulinum toxin containing complexing proteins (AAD 2025) - "One-hundred participants were divided into 5 subgroups for using 5 types of BoNT/A (incobotulinumtoxinA(IncoA), onabotulinumtoxinA(OnaA), abobotulinumtoxinA(AboA), letibotulinumtoxinA(LetiA), and prabotulinumtoxinA(ProboA). AboA which has difference molecular weight can induce only some type of antibody against CPs. IncoA which do not contain complexing protein is not induced antibody against CPs."

Clinical

Sequential use of botulinum toxin A and bovhyaluronidase azoximer in the correction of post-stroke spasticity (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "The results obtained confirm the safety of botulinum therapy and the good tolerability and efficacy of Xeomin in a patient with spasticity with contracture formation after AI. The introduction of ASTHMA after botulinum therapy makes it possible to increase the elasticity of spastic muscles by reducing the severity of fibrous changes and improving motor function."

Journal • Asthma • Cardiovascular • Fibrosis • Immunology • Ischemic stroke • Movement Disorders • Muscle Spasticity • Pulmonary Disease • Respiratory Diseases

PaiNT: A Clinical Trial to Investigate Efficacy and Safety of NT 201 Injections Compared With Placebo Injections in Participants Aged 18 Years and Older With Chronic Nerve Pain After Shingles or Nerve Injury (clinicaltrials.gov) - P2 | N=123 | Active, not recruiting | Sponsor: Merz Therapeutics GmbH | Recruiting ➔ Active, not recruiting

Enrollment closed • Herpes Zoster • Infectious Disease • Neuralgia • Pain • Peripheral Neuropathic Pain • Varicella Zoster

A Pilot Study Testing Onabotulinum Toxin a Versus Incobotulinum Toxin a Injections for Facial Wrinkles (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: Northwestern University | Phase classification: P=N/A ➔ P1 | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Phase classification • Trial completion date • Trial primary completion date

PaiNT: A Clinical Trial to Investigate Efficacy and Safety of NT 201 Injections Compared with Placebo Injections in Participants Aged 18 Years and Older with Chronic Nerve Pain After Shingles or Nerve Injury (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Merz Therapeutics GmbH | Trial completion date: Apr 2025 ➔ Aug 2025 | Trial primary completion date: Jan 2025 ➔ May 2025

Trial completion date • Trial primary completion date • Herpes Zoster • Infectious Disease • Neuralgia • Pain • Peripheral Neuropathic Pain • Varicella Zoster

The Pharmacological Management of Essential Tremor and Its Long-Term Effects on Patient Quality of Life: A Systematic Review. (PubMed, Cureus) - "Based on the studies, pharmacological treatments such as alprazolam, primidone, propranolol, and CX-8998 were found to be efficient in the management of ET...Novel approaches like low-intensity focused ultrasound (LIFU), transcutaneous afferent patterned stimulation (TAPS), and incobotulinumtoxinA injections presented promising results with improved tremor control and minimal side effects. In conclusion, pharmacological treatments for ET provide symptomatic relief but are limited by side effects and reduced long-term efficacy, significantly impacting QoL. Surgical and novel therapeutic options offer enhanced motor control and durability of effects, though they are not universally applicable."

HEOR • Journal • Review • CNS Disorders • Essential Tremor • Movement Disorders

Intradermal Incobotulinum Toxin A for Postbreast Cancer Treatment Asymmetry: A Literature Review and Case Report. (PubMed, J Cosmet Dermatol) - "The review showed promising advances in using botulinum toxin for deformities secondary to oncological treatment in breast cancer patients. The therapy was administered to a 53-year-old patient, resulting in significant aesthetic improvement, especially at the nipple and areola, suggesting that it was a viable option for these patients."

Journal • Review • Aesthetic Medicine • Breast Cancer • Oncology • Pain • Solid Tumor

Are We Missing Something About the Maximum Dosing of Botulinum Toxin Type A1 in Adult and Pediatric Patients with Spasticity? (PubMed, Toxins (Basel)) - "The final point concerns managing the maximum dose of BoNT/A1 in pediatric patients with spasticity who weigh more than 25 kg for incobotulinumtoxinA, or more than 34 kg for abobotulinumtoxinA and onabotulinumtoxinA. No labeled recommendations are given on the weight cut-off for transitioning to adult dosing in pediatric patients."

Journal • Movement Disorders • Muscle Spasticity • Pediatrics

Stable Convergent Polyneuronal Innervation and Altered Synapse Elimination in Orbicularis oculi Muscles from Patients with Blepharospasm Responding Poorly to Recurrent Botulinum Type-A Neurotoxin Injections. (PubMed, Toxins (Basel)) - "We used surgical waste samples from 14 patients treated with repeated injections of either abobotulinumtoxinA (Dysport®) or incobotulinumtoxinA (Xeomin®). Morphological signs of synapse elimination included the presence of retraction bulbs in axons and nerve terminals and a reduced extension of postsynaptic nAChRs. These outcomes suggest that synapse elimination is altered and raise questions on the origin and factors contributing to the plasticity changes observed and the functioning of NMJs."

Journal • CNS Disorders

Successful Treatment of Severe, Poorly Controlled Benign Essential Blepharospasm with DaxibotulinumtoxinA. (PubMed, Ophthalmic Plast Reconstr Surg) - "This case highlights a 57-year-old male with severe, poorly controlled benign essential blepharospasm despite high-dose injections of onabotulinumtoxinA and incobotulinumtoxinA...Notably, the patient experienced 50% to 75% efficacy retention at 3 months postinjection, significantly better than his response to other botulinum toxin type A products. This case suggests that daxibotulinumtoxinA may be an effective treatment for benign essential blepharospasm including patients experiencing poor symptom control with other botulinum toxin type A products."

Journal • CNS Disorders • Dystonia • Movement Disorders

Health Canada Approves XEOMIN (incobotulinumtoxinA) for Treatment of Adults with Post-stroke Lower Limb Spasticity in the Ankle and Foot (Businesswire) - "Merz Therapeutics...announced that Health Canada approved XEOMIN (incobotulinumtoxinA) for the treatment of post-stroke lower limb spasticity involving the ankle and foot in adults."

Canada approval • Muscle Spasticity

Diamond Technique: A Triple Treatment for Neck and Décolletage Rejuvenation. (PubMed, J Cosmet Dermatol) - "While the authors assert the technique's safety and efficacy, the need for controlled studies is crucial. Rigorous, long-term studies are warranted to validate its effectiveness and safety compared with the existing approaches."

Journal • Aesthetic Medicine

LET: Evaluation of Three Types of Injection for the Treatment of Lateral Epicondylalgia (clinicaltrials.gov) - P=N/A | N=13 | Completed | Sponsor: Centre Hospitalier Universitaire de Nīmes | Terminated ➔ Completed

Trial completion • Musculoskeletal Pain

MENOX: Efficacy of Intracavernosal as add-on Therapy to Sildenafil 100 mg on Demand Compared to Sildenafil 100 mg on Demand for the Treatment of Erectile Dysfunction (ED) Not Sufficiently Responsive to Standard Therapy With Phosphodiesterase Type 5 Inhibitors (clinicaltrials.gov) - P2 | N=226 | Completed | Sponsor: Assistance Publique - Hôpitaux de Paris | Active, not recruiting ➔ Completed | Trial completion date: Mar 2025 ➔ Nov 2024 | Trial primary completion date: Mar 2025 ➔ Jul 2024

Trial completion • Trial completion date • Trial primary completion date • Erectile Dysfunction

Complete Improvement of Severe Forearm Complex Regional Pain Syndrome with Six High-Dose Incobotulinumtoxin A Injections: Clinical Implications with Respect to the Literature. (PubMed, Toxins (Basel)) - "Here, a case of CRPS type I, characterized by severe symptoms in the left forearm is presented, showed significant continuous improvement following a series of six repetitive (painful) injections into the finger, hand, and forearm muscles of incoBoNT/A every 3 months, administered at declining doses varying between 500 and 100 U. Remarkably, this treatment regimen led to the complete resolution of pain, vaso- and sudomotor symptoms, and hand dystonia. This highlights the possible efficacy of incoBoNT/A in the treatment of CRPS and encourages the further exploration of incoBoNT/A's role in the successful management of complex pain disorders."

Journal • CNS Disorders • Dystonia • Movement Disorders • Musculoskeletal Pain • Pain